Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma
Open Access
- 1 August 2001
- Vol. 92 (3) , 569-577
- https://doi.org/10.1002/1097-0142(20010801)92:3<569::aid-cncr1356>3.0.co;2-d
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Cancer statistics, 2000CA: A Cancer Journal for Clinicians, 2000
- Gemcitabine Plus Cisplatin, an Active Regimen in Advanced Urothelial Cancer: A Phase II Trial of the National Cancer Institute of Canada Clinical Trials GroupJournal of Clinical Oncology, 1999
- Cisplatin and Gemcitabine Treatment for Malignant Mesothelioma: A Phase II StudyJournal of Clinical Oncology, 1999
- Phase II trial of cisplatin and gemcitabine in advanced squamous-cell carcinoma of the head and neckAnnals of Oncology, 1998
- The role of gemcitabine in the treatment of other tumoursBritish Journal of Cancer, 1998
- Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.Journal of Clinical Oncology, 1997
- Lack of in vivo crossresistance with gemcitabine against drug-resistant murine P388 leukemiasCancer Chemotherapy and Pharmacology, 1996
- A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancerAnnals of Oncology, 1996
- A phase III trial on the therapy of advanced pancreatic carcinoma evaluations of the mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatinCancer, 1990
- Chemotherapy for advanced pancreatic cancer.A comparison of 5-fluorouracil, adriamycin, and mitomycin (fam) with 5-fluorouracil, streptozotocin, and mitomycin (fsm)Cancer, 1986